<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600847</url>
  </required_header>
  <id_info>
    <org_study_id>P04685</org_study_id>
    <secondary_id>EudraCT-Number: 2005-006133-32</secondary_id>
    <nct_id>NCT00600847</nct_id>
  </id_info>
  <brief_title>A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions</brief_title>
  <acronym>AUDACU</acronym>
  <official_title>An Exploratory Phase IV, Randomised, Double-Blind, Placebo Controlled Crossover Study to Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Experimentally Induced Urticaria Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare cold urticaria lesions by thermography, volumetry and
      digital time lapse photography in ACU patients treated with placebo, 5 mg and 20 mg
      desloratadine. Hypothesis: The updosing of desloratadine (20 mg)is more effective in the
      treatment of ACU symptoms as compared to standard doses (5 mg desloratadine) and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the development of urticaria lesions (wheal and flare) induced by TempTest challenge as assessed by digital time lapse photography, volumetry and thermography.</measure>
    <time_frame>90 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in critical temperature thresholds and increase in critical stimulation time thresholds as assessed by standardized TempTest challenge.</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Acquired Cold Urticaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>desloratadine 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>desloratadine 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>single dose for 7 days, oral, 20mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>single dose for 7 days, oral, 5 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single dose for 7 days, oral</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients with ACU for more than 6 weeks. Urticaria symptoms must comprise wheal and
             itch.

          2. History of beneficial effects of antihistaminic treatment.

          3. Age between 18 and 75 years.

          4. Female patients must be using a highly effective method of birth control (such as
             implants, injectables, combined oral contraceptives, some IUDs, sexual
             abstinence,vasectomised partner), or they must be postmenopausal, surgically
             sterilised, or hysterectomised.

          5. Voluntarily signed written informed consent.

        Exclusion Criteria:

          1. The presence of permanent severe diseases, especially those affecting the immune
             system, except ACU

          2. The presence of permanent gastrointestinal condition which may influence the oral
             therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations
             of gastrointestinal tract)

          3. History or presence of epilepsy, significant neurological disorders, cerebrovascular
             attacks or ischemia

          4. History or presence of myocardial infarction or cardiac arrhythmia which requires drug
             therapy

          5. Evidence of severe renal dysfunction

          6. Evidence of significant hepatic disease (liver enzymes twice the upper reference
             value)

          7. History of adverse reactions to DL, loratadine, or other ingredients of the IMP

          8. Presence of active cancer which requires chemotherapy or radiation therapy

          9. Presence of acute urticaria, angioedema, or larynx edema

         10. History or presence of alcohol abuse or drug addiction

         11. Participation in any clinical trial within 4 weeks prior to enrolment

         12. Commitment to an institution in terms of § 40 Abs. 1 Nr. 4 AMG

         13. Intake of antihistamines or leukotriene antagonists within 7 days prior to the
             beginning of the study

         14. Intake of oral corticosteroids within 14 days prior to the beginning of the study

         15. Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before
             beginning of the study

         16. Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergie-Centrum-Charité</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergie-Centrum-Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.urtikaria.net</url>
  </link>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>January 15, 2008</last_update_submitted>
  <last_update_submitted_qc>January 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Marcus Maurer, MD</name_title>
    <organization>Allergie-Centrum-Charité</organization>
  </responsible_party>
  <keyword>urticaria</keyword>
  <keyword>cold urticaria</keyword>
  <keyword>acquired cold urticaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

